


1/17


Fig. 1



REST AVAILABLE COPY

2/17

Fig. 2




EST AVAILABLE COPY


3/17

Fig. 3

A. IL-12 p40



B. IFN- γ



BEST AVAILABLE COPY

4/17

Fig. 4

1826(O)

2006(O)


oligo-4(O)



BEST AVAILABLE COPY

5/17

Fig. 5




REJECT AVAILABILITY COPY


6/17

Fig. 6

A. CD80




B. CD86



REST AVAILABLE COPY

7/17


Fig. 7



BEST AVAILABLE COPY

8/17


Fig. 8



PCT AVAILARIE COPY

9/17


Fig. 9



REST AVAILARIE CORP

10/17

Fig. 10




BEST AVAILABLE COPY


11/17

Fig. 11

A




B



REST AVAILABLE COPY

12/17


Fig. 12



BEST AVAILABLE COPY

13/17


Fig. 13



BEST AVAILABLE COPY

14/17


Fig. 14



TEST AVAILABLE COPY


15/17

Fig. 15



16/17


Fig. 16



BEST AVAILABLE COPY

17/17

Fig. 17



BEST AVAILABLE COPY